TURBOcharging biomanufacturing

 

Synvitrobio is hiring at the Research Associate (BA/BS, MS) and at the Scientist (PhD) level. We're looking for those interested in helping build our synthetic biology technology, with backgrounds in (one or more of) molecular biology, biochemistry, chemical analytics, microbiology, or robotics. Contact Zach Sun (zach [at] synvitrobio [dot] com) if interested.


team:

Zachary Sun, Ph.D.

Zachary Sun, Ph.D.

Zachary Sun has been developing fundamental synthetic biology technologies since 2006, and has published work on MAGE genomic engineering in Nature and on a cell-free prototyping environment in eLife. The latter forms the basis for Synvitrobio. Zachary is a NDSEG Fellow, a DARPA Rising participant, and part of the UCLA/Caltech NIH Medical Scientist Training Program. He holds a PhD in biology from Caltech, an AB in chemical and physical biology with high honors from Harvard, and is a MD candidate (on leave) from UCLA.


technology:

Critical need: Engineering biology can be incredibly powerful for addressing problems in manufacturing and energy, but tools to rationally do so are lacking.   

Technology vision: Synvitrobio’s technology creates a prototyping environment to rapidly speed up design-build-test cycles for bio-based processes and increase the amount of data collected.  

 
The aerospace (left) and electronics (middle) industries use efficient prototyping platforms like wind tunnels and breadboards, allowing rapid design-build-test cycles to drive innovation. Synvitrobio (right) aims to enable a similar paradigm for biomanufacturing.

The aerospace (left) and electronics (middle) industries use efficient prototyping platforms like wind tunnels and breadboards, allowing rapid design-build-test cycles to drive innovation. Synvitrobio (right) aims to enable a similar paradigm for biomanufacturing.

 

Current state-of-the-art: The field has successfully produced chemicals and therapeutics such a 1,3-PDO, farnesene, and artemisinin; however, all test cycles are highly labor intensive and occur primarily in cells.  

Key innovation: Synvitrobio uses cell-free systems as a prototyping environment, thereby allowing the collection of relevant biological data without the restrictions inherent in cellular engineering. Cell-free systems are inexpensive to produce and to use and require significantly less capital to deploy than cellular systems.

Competing technology: Current approaches are driven by high-throughput experiments done completely in cells through “molecular factories.” While sufficient to ultimately reach an end-product, this approach ignores fundamental principles of engineering (modularity, rational design, prototyping environments) and is time and capital intensive.  

First market hypothesis: Bio-based processes for green chemistry.

Potential for impact: We seek to change the way biological engineering is conducted. If successful, our process will become a basis of engineering for a future carbon and energy-neutral bio-economy that relies on biology, rather than petroleum, to drive manufacturing.  

 
Sample complex products (shikimic acid, artemisinin, morphine) difficult to access by synthetic chemistry but potentially accessible by bio-based processes.

Sample complex products (shikimic acid, artemisinin, morphine) difficult to access by synthetic chemistry but potentially accessible by bio-based processes.

 

We're looking for: 

  • Technical collaborators
  • Team members - scientists, engineers
  • Team members - business
  • Interns
  • Funders
  • Joint development partners

Contact: 

zach [at] synvitrobio [dot] com


News Feed: